Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Rougier

Showing results (61-70 of 144) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary noteAnton J Bilchik, Graeme Poston, Steven A Curley, et al.
Plos Medicine|March 3, 2006
Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney diseaseMichael Zeisberg, Mona Khurana, Velidi H Rao, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2010
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinomaFranck Bonnetain, Laetitia Dahan, Emilie Maillard, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 12, 2008
Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trialsFranck Bonnetain, Xavier Paoletti, Sandra Collette, et al.
Hepato-Gastroenterology|September 19, 2009
Prognostic factor of recurrence for resected digestive endocrine tumorsMehdi Ouaïssi, Catherine Julié, Emmanuel Mitry, et al.
BMC Cancer|April 16, 2009
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II studyJean-Luc Raoul, Jean-Luc Van Laethem, Marc Peeters, et al.
Gastroenterologie Clinique Et Biologique|March 2, 2005
Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patientsLaetitia Dahan, Dan Atlan, Olivier Bouché, et al.
Gastroenterologie Clinique Et Biologique|August 24, 2002
[5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer]Julien Taïeb, Thierry Lecomte, Joël Ezenfis, et al.
Journal of Hepatology|December 28, 2011
Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatationJulie Agostini, Stéphane Benoist, Marie Seman, et al.
Cancer Chemotherapy and Pharmacology|April 6, 2010
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancerEmmanuel Mitry, Pascal Hammel, Gaël Deplanque, et al.
Pageof 15

Showing results (61-70 of 144) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary noteAnton J Bilchik, Graeme Poston, Steven A Curley, et al.
Plos Medicine|March 3, 2006
Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney diseaseMichael Zeisberg, Mona Khurana, Velidi H Rao, et al.
European Journal of Cancer (Oxford, England : 1990)|August 21, 2010
Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinomaFranck Bonnetain, Laetitia Dahan, Emilie Maillard, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 12, 2008
Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trialsFranck Bonnetain, Xavier Paoletti, Sandra Collette, et al.
Hepato-Gastroenterology|September 19, 2009
Prognostic factor of recurrence for resected digestive endocrine tumorsMehdi Ouaïssi, Catherine Julié, Emmanuel Mitry, et al.
BMC Cancer|April 16, 2009
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II studyJean-Luc Raoul, Jean-Luc Van Laethem, Marc Peeters, et al.
Gastroenterologie Clinique Et Biologique|March 2, 2005
Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patientsLaetitia Dahan, Dan Atlan, Olivier Bouché, et al.
Gastroenterologie Clinique Et Biologique|August 24, 2002
[5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer]Julien Taïeb, Thierry Lecomte, Joël Ezenfis, et al.
Journal of Hepatology|December 28, 2011
Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatationJulie Agostini, Stéphane Benoist, Marie Seman, et al.
Cancer Chemotherapy and Pharmacology|April 6, 2010
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancerEmmanuel Mitry, Pascal Hammel, Gaël Deplanque, et al.
Pageof 15